Skip to content

Grid Therapeutics Initiates a Phase 2 Investigator-Sponsored Trial of GT103 in Combination with Merck’s Pembrolizumab in Patients with Advanced NSCLC Read more

  • Home
  • About Us
    • Management Team
    • Board of Directors
    • Advisory Board
    • Program Advisors
  • R & D
    • GT103
    • Platform
    • Pipeline
    • Data Warehouse
    • Computational Biology Program
    • Vaccine Program
  • Investors & Partnering
  • Patients & Families
  • News
    • Press Releases
    • Publications & Presentations
  • Contact Us

News

Author: Scott Lyman

Grid Therapeutics Closes Series B Financing

Posted on April 26, 2018April 26, 2018, in News, Press Releases
Read more

Grid Therapeutics Selected by the NCI’s NExT Program to Complete the IND Enabling Nonclinical Work for GT103

Posted on October 31, 2017October 31, 2017, in News, Press Releases
Read more

Grid Therapeutics Collaborates with Catalent to Develop the First Human-Derived Antibody for the Treatment of Cancer

Posted on October 31, 2017, in News, Press Releases
Read more

Grid Therapeutics Closes Series A Financing

Posted on September 20, 2017, in News, Press Releases
Read more

Grid Therapeutics Signs Exclusive License to Develop a Novel Immuno-Oncology Antibody

Posted on August 28, 2017, in News, Press Releases
Read more
  • Home
  • About Us
    • Management Team
    • Board of Directors
    • Advisory Board
    • Program Advisors
  • R & D
    • GT103
    • Platform
    • Pipeline
    • Data Warehouse
    • Computational Biology Program
    • Vaccine Program
  • Investors & Partnering
  • Patients & Families
  • News
    • Press Releases
    • Publications & Presentations
  • Contact Us
© 2023 Grid Therapeutics. All rights reserved.